Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis.
Fu JT, Liu J, Wu WB, Chen YT, Lu GD, Cao Q, Meng HB, Tong J, Zhu JH, Wang XJ, Liu Y, Zhuang C, Sheng C, Shen FM, Liu X, Wang H, Yu Y, Zhang Y, Liang HY, Zhang JB, Li DJ, Li X, Wang ZB, Wang P.
Fu JT, et al.
J Hepatol. 2024 Apr 25:S0168-8278(24)00277-0. doi: 10.1016/j.jhep.2024.04.009. Online ahead of print.
J Hepatol. 2024.
PMID: 38670321